Skip to Content
Morningstar

Chugai Pharmaceutical Co Ltd 4519

Morningstar Rating
Unlock
Stock XTKS Rating as of
JPY 4,925.00 −165.00 (3.24%)
View Full Chart
As of Delayed Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
4519 is trading within a range we consider fairly valued.
Price
JPY 5,090.00
Fair Value
JPY 7,341.00
Uncertainty
High
1-Star Price
JPY 1,873.00
5-Star Price
JPY 9,539.00
Economic Moat
Wtgqc
Capital Allocation
Fnbydrqvm

Bulls Say, Bears Say

Bulls

Chugai is developing cutting-edge antibody technologies and midsize molecules which have the potential to change treatment paradigms that older modalities cannot address.

Bears

Despite Hemlibra’s early success, it could potentially see challenges from longer-acting competitors within a few years.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4519 is a good fit for your portfolio.
Get 7 Days Free

Trading Information

Previous Close Price
JPY 5,090.00
Day Range
JPY 4,896.00–5,101.00
52-Week Range
JPY 3,241.00–6,697.00
Bid/Ask
JPY 4,924.00 / JPY 4,926.00
Market Cap
JPY 8.11 Tril
Volume/Avg
1.9 Mil / 2.5 Mil

Key Statistics

Price/Earnings (Normalized)
26.83
Price/Sales
7.54
Dividend Yield (Trailing)
1.57%
Dividend Yield (Forward)
1.61%
Total Yield
1.57%

Company Profile

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19 patients.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
7,604
Website
http://www.chugai-pharm.co.jp

Competitors

Valuation

View More
Metric
4519
4568
4502
Price/Earnings (Normalized)
 26.8340.2115.49
Price/Book Value
 5.155.480.95
Price/Sales
 7.545.791.55
Price/Cash Flow
 30.0031.388.05
Price/Earnings
4519
4568
4502

Financial Strength

Metric
4519
4568
4502
Quick Ratio
 3.682.740.46
Current Ratio
 4.743.491.06
Interest Coverage
 16,438.8111.761.93
Quick Ratio
4519
4568
4502

Profitability

Metric
4519
4568
4502
Return on Assets (Normalized)
 17.64%7.33%2.86%
Return on Equity (Normalized)
 21.60%13.01%6.13%
Return on Invested Capital (Normalized)
 21.60%11.32%4.78%
Return on Assets
4519
4568
4502
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoKzwbqgybzmJdwdf$709.2 Bil
JNJ
Johnson & JohnsonDwjxgspsHcng$351.2 Bil
MRK
Merck & Co IncFcyzpbdlcSmlqn$317.6 Bil
ABBV
AbbVie IncTzxnnlwDwmgt$291.6 Bil
AZN
AstraZeneca PLC ADRVvplssbnlYlr$210.7 Bil
RHHBY
Roche Holding AG ADRPhfrfzmczHmx$194.6 Bil
NVS
Novartis AG ADRHybvhksnYnxp$190.0 Bil
PFE
Pfizer IncCnwkrrvrWvbh$143.9 Bil
AMGN
Amgen IncWfkhqyrtpcVjmn$141.6 Bil
SNY
Sanofi SA ADRRpybgbdxCqd$113.5 Bil

Sponsor Center